Additionally, 6-month depot LHRH agonists were found to be more cost-effective than their monthly or 3-monthly counterparts.<h4>Conclusion</h4>From a societal perspective, the evidence suggests that degarelix may be a cost-effective option for patients with prostate cancer. This evidence concerns the gene GNRH1 and prostate carcinoma.